Search Results
Dec 10, 2025, 20:53 ET Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025
("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ivonescimab (a PD-1/VEGF bispecific antibody) combined with chemotherapy as a first-line treatment for locally advanced unresectable or metastatic triple-negative breast
More news about: Akeso, Inc.
Dec 10, 2025, 18:30 ET Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
Zolbetuximab + pembrolizumab and chemotherapy as first-line treatment for patients with CLDN18.2-positive, HER2-negative, PD-L1-positive locally advanced unresectable or metastatic G/GEJ adenocarcinoma: Phase 3, double-blind, randomized trial
More news about: Astellas Pharma Inc.
Dec 10, 2025, 18:00 ET Senhwa Biosciences and BeOne Medicines Announces a Clinical Supply Agreement to Address the Challenge of Cold Tumors
a global, multi-center Phase 1b/2a clinical trial to evaluate Senhwa's lead compound Pidnarulex (CX-5461) in combination with BeOne's tislelizumab, a PD-1 inhibitor, in patients with advanced solid tumors, including pancreatic ductal adenocarcinoma (PDAC) and immune checkpoint inhibitor (ICI)-refractory
More news about: Senhwa Biosciences, Inc.
Dec 10, 2025, 17:31 ET Pancreatic Cancer Market Set to Expand During the Forecast Period (2025-2034) as Precision Medicine and Immunotherapy Transform Treatment Landscape | DelveInsight
to increase by 2034.Role of Immune Checkpoint Inhibitors in PDACThe potential of immune checkpoint inhibitors, such as anti-PD-1/PD-L1 therapies, is being explored in PDAC. Clinical trials combining immunotherapy with other treatment modalities (e.g., chemotherapy, radiation,
More news about: DelveInsight Business Research, LLP
Dec 09, 2025, 13:09 ET Phanes Therapeutics to Present Phase 1/2 Study Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026
entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to study spevatamig in combination with Merck's anti-PD-1 therapy, pembrolizumab.The multi-center Phase 1/2 clinical trial of spevatamig (NCT05482893), known as the TWINPEAK study, is currently evaluating
More news about: Phanes Therapeutics, Inc.
Dec 09, 2025, 09:00 ET Parkinson's Foundation Names Centers of Excellence in Ohio and Wisconsin
their regions."The number of people living with PD in the U.S. is expected to rise to 1.2 million by 2030. Currently, care for people with PD is highly varied, and comprehensive care is not widely available. Nearly 40 percent of people with PD do not receive care from a clinician with advanced neurological
More news about: Parkinson's Foundation
Dec 09, 2025, 02:50 ET Phase II Data of Cadonilimab Regimen as Neoadjuvant Therapy for Resectable Gastric Cancer Presented at ESMO Asia 2025
limited efficacy. Cadonilimab, the first PD-1/CTLA-4 bispecific antibody, works by synergistically activating the immune system, achieving a dual blockade of the tumor immune suppressive microenvironment. This mechanism provides a stronger anti-tumor effect compared to PD-1/L1 monotherapies.Currently,
More news about: Akeso, Inc.
Dec 08, 2025, 21:02 ET Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia
ivonescimab arm vs. 59.4% in the control arm). PD-L1 expression levels were also aligned with clinical expectations.The results from the HARMONi-6 study further validate the breakthrough clinical value of the ivonescimab-plus-chemotherapy regimen compared to PD-1-plus chemotherapy regimen. The ivonescimab-plus
More news about: Akeso, Inc.
Dec 08, 2025, 14:45 ET Hemab Therapeutics Announces Positive Complete Phase 2 Data for Sutacimig in Glanzmann Thrombasthenia at ASH 2025; Plans to Advance to Pivotal Phase 3 Study
with GT, with a single related serious adverse event (grade 2 DVT) occurring at the highest dose level (0.9 mg/kg). Anti-drug antibodies impacting PK/PD were observed in five participants; however, titers resolved in one participant with continued dosing, and no associated safety events were reported.Retention:
More news about: Hemab Therapeutics
Dec 08, 2025, 11:30 ET MJFF Initiates Funding for Emerging Therapeutic Targets in Parkinson's Disease
("T2T") Initiative is a multi-year program developed in partnership with leading scientists across academia, industry, venture capital funds and global PD networks to reduce the risk and uncertainty that have historically slowed progress in Parkinson's therapeutic development.
More news about: The Michael J. Fox Foundation for Parkinson's Research
Dec 08, 2025, 07:00 ET HanchorBio Presents First-in-Human Data of HCB101 Monotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma at ASH 2025
of unique biologics with diverse multi-targeting modalities, unleashing both innate and adaptive immunity to overcome the current challenges of anti-PD1/L1 therapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By advancing breakthroughs
More news about: HanchorBio Inc.
Dec 07, 2025, 01:18 ET All Approved Indications of Five Akeso's Innovative Drugs Included in China's Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Drugs
in."Ivonescimab: All 1L and 2L NSCLC Indications Now Covered by NRDLAkeso's first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has successfully secured the inclusion of its new first-line indication for PD-L1-positive non-small cell lung cancer (NSCLC) in the NRDL. In a Phase III head-to-head clinical
More news about: Akeso, Inc.
Dec 06, 2025, 22:40 ET Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
proud to contribute to better care for our patients."TYVYT® (sintilimab injection)TYVYT® (sintilimab injection) is a PD-1 immunoglobulin G4 monoclonal antibody co-developed by Innovent and Eli Lilly and Company. In China, sintilimab has been approved for eight indications
More news about: Innovent Biologics
Dec 05, 2025, 17:45 ET AL-S Pharma Reports Positive Results from Phase 2 Study of AP-101 for the Treatment of ALS, Supporting Plans for a Confirmatory Phase 3 Study
ALS patients. AP-101 received orphan drug designations from FDA, EMA and Swissmedic. The Phase 2 study evaluated safety, tolerability, pharmacodynamic (PD) markers, and pharmacokinetics (PK) of AP-101 in patients with sporadic ALS and in patients with mutations in the SOD1 gene.About AL-S Pharma
More news about: AL-S Pharma AG
Dec 04, 2025, 18:38 ET Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies
Innovent's next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, including the global partnership on IBI363 (PD-1/IL-2α-bias) and IBI343 (CLDN18.2 ADC), and an option for an early-stage program IBI3001 (EGFR/B7H3 ADC). Dr. Hui Zhou, Chief R&D Officer
More news about: Innovent Biologics
Dec 04, 2025, 17:31 ET Basal Cell Carcinoma Market Poised for Steady Growth Throughout Forecast Period (2025-2034) Driven by Novel Drug Approvals and Expanding Patient Pool | DelveInsight
5-fluorouracil and imiquimod, photodynamic therapy using methyl aminolevulinate cream, tazarotene, hedgehog pathway inhibitors (HHPIs), and the PD-1 inhibitor cemiplimab.The U.S. FDA has approved several therapies for advanced BCC, including cemiplimab (LIBTAYO, by Regeneron Pharmaceuticals
More news about: DelveInsight Business Research, LLP
Dec 04, 2025, 10:01 ET New Data from Semaglutide Trials Provides Critical Insights to Guide Next Generation of Therapies Targeting Alzheimer's Pathobiology
International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) in Copenhagen in March 2026.About The Alzheimer's Drug Discovery Foundation (ADDF)Founded in 1998 by Leonard A. and Ronald
More news about: Alzheimer's Drug Discovery Foundation
Dec 04, 2025, 10:00 ET La nueva Serie OPPO Find X9 rompe la barrera de las baterías de 7,000 mAh
AIRVOOC™ de 50 W, disfruta de horas de energía en minutos de carga. La Serie también admite carga de hasta 55 W con cargadores estándar compatibles con USB PD y PPS, lo que permite alcanzar altas velocidades, incluso con accesorios de terceros.La durabilidad también es fundamental en los nuevos dispositivos
More news about: OPPO Mexico
Dec 04, 2025, 08:30 ET ImmunoGenesis Receives $10.8 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Accelerate the Clinical Development of IMGS-001 for Patients with Immune-Excluded Tumors with High Unmet Need
cytotoxic immune checkpoint inhibitor targeting PD-L1 and PD-L2. The drug is engineered to overcome immune resistance in immune-excluded tumors, as it has the potential to eliminate immunosuppressive cells in the tumor microenvironment and provide best-in-class PD-1 pathway blockade. Preclinical data showed
More news about: Immunogenesis Inc.
Dec 04, 2025, 08:30 ET Caris Life Sciences to Showcase 19 Studies at the 2025 San Antonio Breast Cancer Symposium
Breast Cancer. #PS2-08-04Poster Session 2. December 10, 2025. 5:00 – 6:30 PM CSTChemokine signatures improve PD-L1-based prediction of pembrolizumab response in triple-negative breast cancer. #PS2-08-14Poster Session 2. December 10, 2025.
More news about: Caris Life Sciences
Dec 04, 2025, 08:13 ET 新橋生物宣佈將在ESMO-IO大會上公佈Ragistomig擴展性1期臨床數據
Ragistomig是一款4-1BB × PD-L1雙特異性抗體，旨在治療使用檢查點抑制劑後病情復發或效果欠佳的患者。作為百億美元級藥物，檢查點抑制劑雖應用廣泛，但時常面臨著耐藥問題Ragistomig的1期研究已達目標：延長至每六週一次的（Q6W）新給藥間隔方案在對PD-L1抑制劑無應答的患者中表現出強效抗腫瘤活性，且安全性特徵更優包含CD8+細胞增殖和記憶T細胞活化等免疫學數據的中期結果，預計將於格林威治時間2025年12月10日下午5點30分在歐洲腫瘤內科學會免疫腫瘤學大會（ESMO-IO）上以海報形式公佈
More news about: 新橋生物
Dec 04, 2025, 06:50 ET 科倫博泰與Crescent Biopharma 達成合作，共同開發及商業化新型腫瘤治療手段
CR-001（亦稱SKB118）CR-001是一款四價雙特異性抗體，目前正開發用於治療實體瘤。其結合了腫瘤學中兩種互補且經過驗證的作用機制——PD-1和VEGF阻斷，其中對PD-1檢查點的抑制可恢復T細胞識別和摧毀腫瘤細胞的能力，而VEGF阻斷可減少對腫瘤細胞的血液供應並抑制腫瘤生長。在臨床前研究中，CR-001在VEGF存在的情況下顯示出提升PD-1的結合和信號阻斷能力的協同藥理作用，並具有強大的抗腫瘤活性。CR-001的抗VEGF活性還可能使腫瘤部位的血管正常化，有望提高聯合療法（例如CR-001與ADC聯用）的定位及有效性。一項CR-001治療實體瘤患者的全球I/II期試驗預計於2026年第一季度啟動。
More news about: 四川科倫博泰生物醫藥股份有限公司
Dec 03, 2025, 19:00 ET High Response in Bladder Cancer: Immvira Announced Its MVR-T3011 Latest Clinical Results in BCG-Unresponsive Bladder Cancer Patients at 2025 Annual Meeting of the Society of Urologic Oncology
breakthrough in HSV-1-based oncolytic immunotherapy. Its proprietary "3-in-1" design unites a replication-competent, tumor-lytic HSV-1 backbone with anti-PD-(L)1 antibody and IL-12, enabling it simultaneously to lyse tumor cells and stimulate innate and adaptive immunity. MVR-T3011 has demonstrated its adaptability
More news about: ImmVira
Dec 03, 2025, 07:34 ET Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders
19th World Immune Regulation Meeting ("WIRM") in Davos, Switzerland. These data showed progressive up-regulation of multiple exhaustion markers (PD-1, LAG-3, TIGIT, TIM-3, CD39) with repeated antigen stimulation, alongside changes in cytokine profiles in PAIS patients versus healthy controls. In simple
More news about: Virax BioLabs Group Limited
Dec 02, 2025, 18:54 ET Accord Healthcare 宣佈推出 Denosumab∇ - 骨骼健康領域第二款生物相似藥
JUBEREQ 與 Xgeva 的療效。該研究證實，兩種產品的藥代動力學參數具有可比性。4此項第三期研究為一項隨機、雙盲、活性對照、平行組、多中心研究，旨在比較 OSVYRTI 與 Prolia 在絕經後骨質疏鬆症女性患者中的藥代動力學/藥效學 (PK/PD)、療效及安全性。臨床研究結果顯示，OSVYRTI 以及其參照產品 Prolia 高度相似，在藥代動力學、藥效學、安全性及療效方面均無臨床意義上的差異。2.4Accord Healthcare 簡介Accord Healthcare 是英國與歐洲發展最迅速的學名藥與生物相似藥製藥公司之一。憑藉對品質、可接達性與可持續性的堅持，Accord
More news about: Accord Healthcare